BIOTECHNOLOGY & PUBLIC HEALTH
BIOTECHNOLOGY & PUBLIC HEALTH
Stacks Image 515
TODD BIXBY
CO-FOUNDER & CHIEF EXECUTIVE OFFICER
PLANETARY GENETICS
A private holding company and innovation engine advancing biotech startups and new ventures. Management is maintaining and building agile execution teams to deliver data and IP packages that generate value inflection and catalyze new commercial opportunities in our mission spaces.
Discover more at www.planetary-genetics.com.
CO-FOUNDER & PRINCIPAL CONSULTANT
ROSSI BIXBY + ASSOCIATES
Specialized biotechnology, biopharma and communications consulting.
Visit www.rossibixby.com to learn more about our concierge services:
- New Product Development and Commercial Strategy
- Technology Analysis and Commercial Diligence
- Technology and Strategic Partnerships
- Technical and Strategic Communications
Stacks Image 462
TODD BIXBY
CO-FOUNDER & CHIEF EXECUTIVE OFFICER | PLANETARY GENETICS
A private holding company and innovation engine advancing biotech startups and new ventures. Management is maintaining and building agile execution teams to deliver data and IP packages that generate value inflection and catalyze new commercial opportunities in our mission spaces.
Discover more at www.planetary-genetics.com.
CO-FOUNDER & PRINCIPAL CONSULTANT | ROSSI BIXBY + ASSOCIATES
Specialized biotechnology, biopharma and communications consulting.
Visit www.rossibixby.com to learn more about our concierge services:
- New Product Development and Commercial Strategy
- Technology Analysis and Commercial Diligence
- Technology and Strategic Partnerships
- Technical and Strategic Communications
Stacks Image 524
TODD BIXBY
CO-FOUNDER & CHIEF EXECUTIVE OFFICER | PLANETARY GENETICS
A private holding company and innovation engine advancing biotech startups and new ventures. Management is maintaining and building agile execution teams to deliver data and IP packages that generate value inflection and catalyze new commercial opportunities in our mission spaces.
Discover more at www.planetary-genetics.com.
CO-FOUNDER & PRINCIPAL CONSULTANT | ROSSI BIXBY + ASSOCIATES
Specialized biotechnology, biopharma and communications consulting.
Visit www.rossibixby.com to learn more about our concierge services:
- New Product Development and Commercial Strategy
- Technology Analysis and Commercial Diligence
- Technology and Strategic Partnerships
- Technical and Strategic Communications
HIGHLIGHTS
HIGHLIGHTS
Biotechnology and public health professional with over 20 years experience developing, deploying and evaluating technologies applicable to human and animal health, food, and environmental interventions, as well as, national security, conservation, sustainable agriculture, waste-to-value, biofuels, and consumer products. Multi-disciplinary expertise gained functioning in technology analysis, basic and applied research, new product development, project management, marketing, business development, strategic alliances, and leadership roles.
Biotechnology and public health professional with over 20 years experience developing, deploying and evaluating technologies applicable to human and animal health, food, and environmental interventions, as well as, national security, conservation, sustainable agriculture, waste-to-value, biofuels, and consumer products. Multi-disciplinary expertise gained functioning in technology analysis, basic and applied research, new product development, project management, marketing, business development, strategic alliances, and leadership roles.
CURRENT TECHNOLOGY DEVELOPMENT INITIATIVES
HEALTH
ENVIRONMENT
  • Advancing technologies for health and safety testing, environmental cleanup, ocean conservation, and natural products chemistries discovery
FOOD
HEALTH
  • Engineering SARS-CoV-2 Sewer Surveillance Systems and environmental testing platforms to help contain the spread of COVID-19 and future threats (redirect to www.planetary-genetics.com)
ENVIRONMENT
  • Advancing technologies for health and safety testing, environmental cleanup, ocean conservation, and natural products chemistries discovery
FOOD
HEALTH
  • Engineering SARS-CoV-2 Sewer Surveillance Systems and environmental testing platforms to help contain the spread of COVID-19 and future threats (redirect to www.planetary-genetics.com)
ENVIRONMENT
  • Advancing technologies for health and safety testing, environmental cleanup, ocean conservation, and natural products chemistries discovery
FOOD
UNIQUE QUALIFICATIONS & EXPERIENCE
TECHNOLOGY ANALYSIS | M&A DILIGENCE | TECHNOLOGY INNOVATION
Participated in technology diligence to support acquisition or internal development and deployment of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA and USFWS regulators:
  • AquaBounty genetically engineered salmon, first GE food animal approved for human consumption (partial acquisitions)
  • Oxitec genetically engineered insects to fight agricultural pests, infectious disease carrying insects, and invasive species ($160M acquisition)
  • ViaGen cloning for food animals (subsidiary of $110M Trans Ova Genetics acquisition)
  • ViaGen Pets established for cloning of companion animals and programs enabling endangered species population expansion with cloning of archival veterinary specimens to enhance population genetics (Intrexon, ViaGen) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Trans Ova Genetics leading provider of bovine reproductive technologies ($110M acquisition)
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec human and animal molecular vaccine platform (acquisition)
  • Intrexon and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® platform for protein engineering and gene switches for control of protein production [microbes, plants, animals, humans]

HEALTH TECHNOLOGY
  • Developed groundbreaking FDA cleared products at Gen-Probe including current molecular tests ensuring safety of U.S. blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first combined Chlamydia and Gonorrhea molecular tests, eliminating need for male genital swabbing using male/female urine specimens
  • Developed and advanced numerous diagnostic, therapeutic, and vaccine health technologies with molecular, genetic, and genome engineering platforms

GLOBAL PUBLIC HEALTH & NATIONAL SECURITY
  • Pioneered HIV CD4 mobile testing interventions in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Epidemic responses: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Expertise in molecular epidemiology, epidemic intelligence, environmental health, infectious disease control, and biological threat detection systems
  • Advanced numerous biodefense, biosecurity, and medical countermeasure technologies: diagnostics and detection systems, vaccines, therapeutics
  • Infectious disease testing and vector control interventions for mosquito-borne diseases (Gen-Probe, St. Gabriel’s Hospital - Malawi, Intrexon, Oxitec)

FOOD TECHNOLOGY
  • Advanced food biotechnology for first-in-class synthetic biology enabled food products and agricultural innovations at Intrexon
  • Deep expertise with gene-edited, genetically engineered, and cloned organisms serving as first-in-class for US FDA and USDA regulators

ENVIRONMENTAL INTERVENTIONS & CONSERVATION
  • Developed multiple environmental threat detection systems for biosecurity (Gen-Probe, Nanogen - Vectrant)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (COCs) (Intrexon)
TECHNOLOGY ANALYSIS | M&A DILIGENCE | TECHNOLOGY INNOVATION
Participated in technology diligence to support acquisition or internal development and deployment of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA and USFWS regulators:
  • AquaBounty genetically engineered salmon, first GE food animal approved for human consumption (partial acquisitions)
  • Oxitec genetically engineered insects to fight agricultural pests, infectious disease carrying insects, and invasive species ($160M acquisition)
  • ViaGen cloning for food animals (subsidiary of $110M Trans Ova Genetics acquisition)
  • ViaGen Pets established for cloning of companion animals and programs enabling endangered species population expansion with cloning of archival veterinary specimens to enhance population genetics (Intrexon, ViaGen) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Trans Ova Genetics leading provider of bovine reproductive technologies ($110M acquisition)
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec human and animal molecular vaccine platform (acquisition)
  • Intrexon and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® platform for protein engineering and gene switches for control of protein production [microbes, plants, animals, humans]

HEALTH TECHNOLOGY
  • Developed groundbreaking FDA cleared products at Gen-Probe including current molecular tests ensuring safety of U.S. blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first combined Chlamydia and Gonorrhea molecular tests, eliminating need for male genital swabbing using male/female urine specimens
  • Developed and advanced numerous diagnostic, therapeutic, and vaccine health technologies with molecular, genetic, and genome engineering platforms

GLOBAL PUBLIC HEALTH & NATIONAL SECURITY
  • Pioneered HIV CD4 mobile testing interventions in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Epidemic responses: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Expertise in molecular epidemiology, epidemic intelligence, environmental health, infectious disease control, and biological threat detection systems
  • Advanced numerous biodefense, biosecurity, and medical countermeasure technologies: diagnostics and detection systems, vaccines, therapeutics
  • Infectious disease testing and vector control interventions for mosquito-borne diseases (Gen-Probe, St. Gabriel’s Hospital - Malawi, Intrexon, Oxitec)

FOOD TECHNOLOGY
  • Advanced food biotechnology for first-in-class synthetic biology enabled food products and agricultural innovations at Intrexon
  • Deep expertise with gene-edited, genetically engineered, and cloned organisms serving as first-in-class for US FDA and USDA regulators

ENVIRONMENTAL INTERVENTIONS & CONSERVATION
  • Developed multiple environmental threat detection systems for biosecurity (Gen-Probe, Nanogen - Vectrant)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (COCs) (Intrexon)
TECHNOLOGY ANALYSIS | M&A DILIGENCE | TECHNOLOGY INNOVATION
Participated in technology diligence to support acquisition or internal development and deployment of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA and USFWS regulators:
  • AquaBounty genetically engineered salmon, first GE food animal approved for human consumption (partial acquisitions)
  • Oxitec genetically engineered insects to fight agricultural pests, infectious disease carrying insects, and invasive species ($160M acquisition)
  • ViaGen cloning for food animals (subsidiary of $110M Trans Ova Genetics acquisition)
  • ViaGen Pets established for cloning of companion animals and programs enabling endangered species population expansion with cloning of archival veterinary specimens to enhance population genetics (Intrexon, ViaGen) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Trans Ova Genetics leading provider of bovine reproductive technologies ($110M acquisition)
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec human and animal molecular vaccine platform (acquisition)
  • Intrexon and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® platform for protein engineering and gene switches for control of protein production [microbes, plants, animals, humans]

HEALTH TECHNOLOGY
  • Developed groundbreaking FDA cleared products at Gen-Probe including current molecular tests ensuring safety of U.S. blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first combined Chlamydia and Gonorrhea molecular tests, eliminating need for male genital swabbing using male/female urine specimens
  • Developed and advanced numerous diagnostic, therapeutic, and vaccine health technologies with molecular, genetic, and genome engineering platforms

GLOBAL PUBLIC HEALTH & NATIONAL SECURITY
  • Pioneered HIV CD4 mobile testing interventions in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Epidemic responses: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Expertise in molecular epidemiology, epidemic intelligence, environmental health, infectious disease control, and biological threat detection systems
  • Advanced numerous biodefense, biosecurity, and medical countermeasure technologies: diagnostics and detection systems, vaccines, therapeutics
  • Infectious disease testing and vector control interventions for mosquito-borne diseases (Gen-Probe, St. Gabriel’s Hospital - Malawi, Intrexon, Oxitec)

FOOD TECHNOLOGY
  • Advanced food biotechnology for first-in-class synthetic biology enabled food products and agricultural innovations at Intrexon
  • Deep expertise with gene-edited, genetically engineered, and cloned organisms serving as first-in-class for US FDA and USDA regulators

ENVIRONMENTAL INTERVENTIONS & CONSERVATION
  • Developed multiple environmental threat detection systems for biosecurity (Gen-Probe, Nanogen - Vectrant)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (COCs) (Intrexon)
  • Deep expertise with gene-edited, genetically engineered, and cloned organisms serving as first-in-class for EPA and USFWS regulators
BIOSKETCH
Mr. Bixby has been advancing biotechnology to benefit the public health across applications spanning food tech, diagnostics, therapeutics, biodefense, bioremediation, and invasive species control interventions, globally for over 20 years.

His experience as a life sciences, biotechnology and public health professional has focused on development of advanced technologies with applications applicable to human and animal health, food, and environmental interventions, as well as, national security, conservation, sustainable agriculture, waste-to-value, biofuels, and consumer products.

He has cross-functional experience developing, deploying and evaluating technologies for clinical, public health, and biodefense programs including biological threat detection systems and various therapeutic and vaccine medical countermeasures. Additionally, his technical and commercial experience with international launching of advanced technologies has been informed by having helped develop multiple infectious disease diagnostics including molecular tests for the safety of the U.S. blood supply and other nations, which also greatly enhanced later efforts to evaluate and deploy critical diagnostic interventions in low resource settings across developing countries in Sub-Saharan Africa.

His world view has been further formed through graduate research in epidemiology with strong focus in governmental and regulatory policies affecting environmental and public health, biotechnology, synthetic biology and genetic engineering. Mr. Bixby has gained multi-disciplinary expertise functioning in technology analysis, basic and applied research, new product development, project management, marketing, business development, strategic alliances, and leadership roles.

Mr. Bixby is also a great proponent of interventions aimed at Public Health and One Health, Planetary Health.
LINKS
CONTACT
info@toddbixby.com

ADVANCING BIOTECHNOLOGY FOR PUBLIC HEALTH, ONE HEALTH, PLANETARY HEALTH

ADVANCING BIOTECHNOLOGY FOR PUBLIC HEALTH, ONE HEALTH, PLANETARY HEALTH

Stacks Image 152
We can’t solve problems by using the same kind of thinking we used when we created them.
A.E.
We can’t solve problems by using the same kind of thinking we used when we created them.
A.E.

ONE HEALTH, PLANETARY HEALTH.

ONE HEALTH focuses on the interconnectedness of the health and well-being of humans, animals and ecosystems. Our health depends on healthy connections between those ecosystems.

PLANETARY HEALTH reframes the ENVIRONMENTAL and GLOBAL HEALTH challenges in terms that help make them self-evident.

ENVIRONMENTAL HEALTH and PUBLIC HEALTH are ultimately measures of the PLANET'S GENETICS, which is to say ALL THE GENES, interacting with each other and their environments under the pressure of time.

Learn more here about how PLANETARY GENETICS LLC is advancing new technology ventures for a healthier planet.

Stacks Image 492

HUMANS

Stacks Image 495

ANIMALS

Stacks Image 498

ECOSYSTEMS

NEWS

2 OCT 2020: ROSSI BIXBY + ASSOCIATES – We are pleased to announce availability to support new projects moving into Fall of 2020 and early 2021. We are grateful for the wonderful response to our formation this past Spring and are excited for the increased bandwidth to support initiatives we think make a difference. Feel free to visit www.rossibixby.com and our LinkedIn page to connect. Looking forward!

14 MAY 2020: ROSSI BIXBY + ASSOCIATES | IMPACT & STRATEGIC CONSULTING announced our official formation in Spring 2020. Visit www.rossibixby.com to learn more. We're excited.

COVID-19 RESPONSE UPDATE (MAR 2020): At this critical time, I am happy to report the Planetary Genetics team is working to respond to the COVID pandemic by advancing diagnostics for quantitative neutralizing antibodies to SARS-CoV-2. Read more here.

CONFERENCES: Attended the INTERNATIONAL PLANT & ANIMAL GENOME CONFERENCE in San Diego, CA, January 11-15, 2020. Looking forward to re-connecting. Request a follow-up meeting here.

PLANETARY GENETICS LLC announced its formation in May 2019. Learn more about our mission at www.planetary-genetics.com.
We can’t solve problems by using the same kind of thinking we used when we created them.
A.E.

EVENTS

Given scheduling changes associated with COVID-19, this events schedule is in flux. Look forward to electronic connections on a path to returning to social interactions. Feel free to follow-up regarding meeting related events via email to info@toddbixby.com.
International Plant & Animal Genome Conference
The International Conference on the Status of Plant & Animal Genome Research

San Diego, CA
January 11-15, 2020
Beta Space
The unconvention for the space settlement community™

Mojave Desert, CA
To be rescheduled
American Public Health Association Annual Meeting
Creating the Healthiest Nation

San Francisco, CA
October 24-28, 2020

***

Association for Molecular Pathology Annual Meeting

Vancouver, British Columbia, Canada
November 17-21, 2020